Enck Robert E, Abushahin Fadi, Bossaer John B
Department of Internal Medicine, Division of Hematology/Oncology, East Tennesse State University College of Medicine, Johnson City, TN, USA.
J Oncol Pharm Pract. 2014 Apr;20(2):137-40. doi: 10.1177/1078155213480069. Epub 2013 May 14.
Imatinib mesylate has been associated with the changes in bone turnover. We report a case of the development of tissue calcification in a patient on long-term therapy with this drug. A 48-year-old male patient with gastrointestinal stromal tumor and liver metastasis complained of abdominal pain. His treatment included hepatic artery chemoembolization and partial hepatectomy in addition to chronic imatinib mesylate for 4 years. On physical examination, he had a peritoneal mass just beneath the laparotomy incision scar that, after resection, was found to be dystrophic bone formation. Based on the previous studies suggesting bone changes due to chronic therapy with imatinib mesylate, we believe that the patient's new bone formation was causally related to the use of this drug. To our knowledge, there are no similar reported cases in the literature.
甲磺酸伊马替尼与骨转换变化有关。我们报告了1例长期使用该药物治疗的患者发生组织钙化的病例。1例48岁男性胃肠道间质瘤伴肝转移患者诉腹痛。他的治疗包括肝动脉化疗栓塞术和部分肝切除术，此外还接受了4年的甲磺酸伊马替尼长期治疗。体格检查发现，他在剖腹手术切口瘢痕下方有一个腹膜肿块，切除后发现是营养不良性骨形成。基于先前研究提示甲磺酸伊马替尼长期治疗可导致骨改变，我们认为该患者的新骨形成与此药使用存在因果关系。据我们所知，文献中尚无类似病例报道。
